ResMed/$RMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ResMed
ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
- Ticker
- $RMD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 11,370
- Headquarters
- San Diego, United States
- Website
- www.resmed.com
ResMed Metrics
BasicAdvanced
$32B
20.94
$10.98
-
$2.46
1.15%
Price and volume
Market cap
$32B
52-week high
$277.67
52-week low
$180.27
Average daily volume
1.2M
Dividend rate
$2.46
Financial strength
Current ratio
2.65
Quick ratio
1.498
Long term debt to equity
0.07
Total debt to equity
0.103
Dividend payout ratio (TTM)
22.40%
Profitability
EBITDA (TTM)
2,096.265
Gross margin (TTM)
61.69%
Net profit margin (TTM)
27.79%
Operating margin (TTM)
33.60%
Effective tax rate (TTM)
20.81%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
14.58%
Return on equity (TTM)
26.40%
Valuation
Price to earnings (TTM)
20.944
Price to revenue (TTM)
5.805
Price to book
5.53
Price to tangible book (TTM)
12.66
Price to free cash flow (TTM)
20.951
Free cash flow yield (TTM)
4.77%
Free cash flow per share (TTM)
10.975
Dividend yield (TTM)
1.07%
Forward dividend yield
1.15%
Growth
Revenue change (TTM)
9.04%
Earnings per share change (TTM)
12.37%
3-year revenue growth (CAGR)
9.43%
10-year revenue growth (CAGR)
11.72%
3-year earnings per share growth (CAGR)
21.31%
10-year earnings per share growth (CAGR)
16.18%
10-year dividend per share growth (CAGR)
3.63%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Analyst projections of the future price of ResMed stock.
Bulls say / Bears say
In Q1 FY27, core constant-currency revenue grew 7%, non-GAAP EPS rose 14% and non-GAAP gross margin expanded by 50 basis points. That combination points to continued sales growth with improving profitability. (ResMed)
UK pilot evaluations found ResMed’s AirConnect Dx cut referral-to-diagnosis time by 90–97% and enabled up to three times the diagnostic capacity. If this helps reduce bottlenecks, more people with suspected sleep apnoea could reach treatment sooner. (ResMed)
ResMed’s partnership with ŌURA directs members with breathing concerns towards sleep-health information and care pathways. With the company estimating that 80% of US sleep-apnoea cases remain undiagnosed, better awareness could support a larger pool of future patients. (ResMed)
After a safety correction and FDA recall involving Astral ventilators, ResMed suspended sales and included a $75 million impact in its FY27 outlook. The forecast of $5.75–$5.85 billion in revenue was below analysts’ expectations, leaving a meaningful operational and growth headwind. (Reuters)
Management has flagged rising freight, fuel and electronic-component costs, particularly for older devices, and said productivity savings can no longer offset inflation on their own. Those pressures could make planned gross-margin gains harder to deliver. (Stock Analysis)
ResMed warns that GLP-1 weight-loss drugs could reduce sleep-apnoea severity for some patients if weight loss is maintained, potentially weakening demand over time. The drugs are also being marketed for treatment of sleep apnoea, adding to the risk from alternative therapies. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
Upcoming events
ResMed News
AllArticlesVideos
Funds containing ResMed
AllEURUSDGBP
Fund name | Fund size | $RMD weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.55% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.50% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.50% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.45% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.